Skip to content
Integrilin(eptifibatide)
Integrilin (eptifibatide) is a protein pharmaceutical. Eptifibatide was first approved as Integrilin on 1998-05-18. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA. It has been approved in Europe to treat myocardial infarction and unstable angina.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eptifibatide
Tradename
Company
Number
Date
Products
INTEGRILINMerck Sharp & DohmeN-020718 DISCN1998-05-18
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
eptifibatideANDA2021-03-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coronary diseaseD003327
myocardial infarctionEFO_0000612D009203I21
unstable anginaEFO_1000985D000789I20.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AC: Platelet aggregation inhibitors excl. heparin
B01AC16: Eptifibatide
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
J1327
Injection, eptifibatide, 5 mg
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I211214
Coronary artery diseaseD003324I25.133
Non-st elevated myocardial infarctionD00007265811
AngioplastyD01713011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute coronary syndromeD054058EFO_0005672325
Ischemic strokeD000083242224
Myocardial ischemiaD017202EFO_1001375I20-I2511
Cardiovascular diseasesD002318EFO_0000319I9811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9133
Unstable anginaD000789EFO_1000985I20.022
Brain infarctionD020520EFO_0004277I6322
PneumoniaD011014EFO_0003106J1811
Coronary diseaseD00332711
Septic shockD012772A48.311
Inferior wall myocardial infarctionD056989EFO_100098311
Sickle cell anemiaD000755EFO_0000697D57111
St elevation myocardial infarctionD00007265711
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEPTIFIBATIDE
INNeptifibatide
Description
Eptifibatide is a synthetic homodetic cyclic peptide comprising N(alpha)-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulfide bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/IIIa receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. It has a role as a platelet aggregation inhibitor and an anticoagulant. It is an organic disulfide, a macrocycle and a homodetic cyclic peptide.
Classification
Protein
Drug classpeptides: platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O
Identifiers
PDB
CAS-ID188627-80-7
RxCUI75635
ChEMBL IDCHEMBL1174
ChEBI ID291902
PubChem CID448812
DrugBankDB00063
UNII IDNA8320J834 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,733 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,702 adverse events reported
View more details